SLC25A21

Mitochondrial 2-oxodicarboxylate carrier · Q9BQT8 · SLC25A21 on Sugi Atlas →

3 patent compounds predicted against SLC25A21, 1 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Diallyl Sulfide Diallyl Sulfide (SCHEMBL27897274) 0.42 1/20

Clinical trials — most relevant to SLC25A21 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Phase III Trial of Coenzyme Q10 in Mitochondrial Disease PHASE3COMPLETED
The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC PHASE1/PHASE2UNKNOWN
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder PHASE2WITHDRAWN
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
EPI-743 for Metabolism or Mitochondrial Disorders PHASE1/PHASE2COMPLETED
Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease nanNOT_YET_RECRUITING
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Genetic Variations That Increase the Risk for Calcium Kidney Stones: a Family-based Study nanCOMPLETED
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Survey on Supplement Use in Mitochondrial Disease nanCOMPLETED
Identification of New Candidate Genes in Patients With Mitochondrial Disease by High Resolution Chromosome Analysis on DNA Chip nanCOMPLETED
The Natural History of Mitochondrial Diseases nanRECRUITING
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes nanNOT_YET_RECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) nanRECRUITING
GDF-15 as a Biomarker for Mitochondrial Disease nanCOMPLETED
Mitoquines in COPD nanUNKNOWN
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders nanCOMPLETED
Effects of Parenteral L-carnitine Supplementation in Premature Neonates nanCOMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Ccf mtDNA as a Neurodegenerative Biomarker nanUNKNOWN
Natural History Study of FDXR Mutation-related Mitochondriopathy nanCOMPLETED
Human Mitochondrial Stress-driven Obesity Resistance nanCOMPLETED
Calf Muscle Strength in Mitochondrial Diseases nanCOMPLETED
Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides nanCOMPLETED
The Genetics of Diabetes in Southern California Chinese Americans nanWITHDRAWN

Related proteins — ESM-2 sequence neighbours (a SLC25A21 binder may also engage these)

ProteinNameSimilarity
Q5RFB7 1.000 Q5RFB7 →
A0JN87 0.997 A0JN87 →
Q8BZ09 0.984 Q8BZ09 →
Q9M038 0.980 Q9M038 →
Q99JD3 0.979 Q99JD3 →
Q08DK4 0.968 Q08DK4 →
Q9D6M3 0.968 Q9D6M3 →
Q9H936 0.966 Q9H936 →
A0A0G2K5L2 0.965 A0A0G2K5L2 →
Q5RD81 0.964 Q5RD81 →
P56500 0.963 P56500 →
Q9H1K4 0.961 Q9H1K4 →
P70406 0.960 P70406 →
Q9W720 0.960 Q9W720 →
Q7K566 0.959 Q7K566 →
Q9DB41 0.959 Q9DB41 →
Q9W725 0.958 Q9W725 →
Q5ZKP7 0.958 Q5ZKP7 →
Q4V9P0 0.957 Q4V9P0 →
Q96CQ1 0.957 Q96CQ1 →
Q6DG32 0.954 Q6DG32 →
Q922G0 0.953 Q922G0 →
Q9D6D0 0.953 Q9D6D0 →
G3YAF3 0.953 G3YAF3 →
O77792 0.952 O77792 →
Q505J6 0.952 Q505J6 →
G3XP90 0.952 G3XP90 →
Q9BSK2 0.952 Q9BSK2 →
Q9H2D1 0.951 Q9H2D1 →
Q8BMG8 0.951 Q8BMG8 →